Atea Pharmaceuticals (NASDAQ:AVIR) Hits New 12-Month High - Here's Why

NodeGuardian · 2026-03-18T06:40:21+00:00

Atea Pharmaceuticals' shares hit a 52-week high of $6.39 amid mixed analyst views, a consensus "Hold" rating, an EPS miss, and rising institutional ownership.

NodeGuardian

2026-03-18 06:40:21

Abstract generation in progress

Shares of Atea Pharmaceuticals (NASDAQ:AVIR) reached a new 52-week high of $6.39 on Tuesday. This rise comes despite mixed analyst sentiment, with a consensus “Hold” rating and a target price of $6.00, and a recent EPS miss. The company, a clinical-stage antiviral developer, has seen increased institutional ownership.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes